Enterprise Value
2.932B
Cash
201.2M
Avg Qtr Burn
-35.12M
Short % of Float
22.08%
Insider Ownership
0.54%
Institutional Own.
-
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMCIVREE™ (Setmelanotide) Details Rare genetic disease, Bardet-Biedl syndrome | Approved Update | |
Approved Quarterly sales | ||
Approved Quarterly sales | ||
sNDA Submission | ||
IMCIVREE™ (Setmelanotide) Details Rare genetic disease | NDA FDA meeting | |
Phase 3 Data readout | ||
LB54640 Details Obesity | Phase 2 Data readout | |
Phase 2 Data readout | ||
RM-718 Details Obesity | Phase 1 Data readout |